Virtual Reality Therapeutic EaseVRx Named Breakthrough Device by FDA

Virtual Reality Therapeutic EaseVRx Named Breakthrough Device by FDA
The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to AppliedVR's EaseVRx, a virtual reality therapeutic, recognizing its potential for helping to manage both therapy-resistant fibromyalgia and chronic intractable lower back pain. This designation is intended to help speed up the development of devices that may substantively improve medical care for serious diseases or enable their diagnosis. EaseVRx is one of the first virtual reality or VR-based technologies to receive breakthrough device designation for pain-associated conditions. "Today’s FDA designation demonstrates that health experts across the spectrum recognize the therapeutic potential of VR as a viable treatment for pain," Matthew Stoudt, CEO and co-founder of AppliedVR, said in a press release. EaseVRx uses VR to help people with chronic pain learn skills for self-management. The program is grounded in principles from cognitive behavioral therapy, a type of talk therapy, and other behavioral methods. The overall goal of the program — which was designed by AppliedVR, in partnership w
Subscribe or to access all post and page content.